Announcement on Preliminary Earnings Estimate for 2025
Filed with SSE · · 4 pages · Chinese
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. on 6ix
Earlier from Sunshine Guojian Pharmaceutical (Shanghai)
- Announcement on Voluntary Disclosure of the Approval of the New Drug Marketing Application for Anmuqita Monoclonal Antibody Injection
- Earnings Preannouncement for 2025
- Announcement on Vesting Results of the 1st Vesting Period for the Initial Grant of the 2024 Restricted Stock Incentive Plan
- Announcement on Changes in Core Technical Personnel
- Announcement on Shareholding Reduction Plan for Shareholders
Later from Sunshine Guojian Pharmaceutical (Shanghai)
- Announcement on Voluntary Disclosure of New Drug Application Acceptance for the Recombinant Anti-IL-4Rα Humanized Monoclonal Antibody Injection
- Announcement on Equity Change of Shareholders Reaching 1% Scale and Results of Shareholding Reduction
- Announcement on Resolutions of the 14th Meeting of the 5th Board of Directors
- Announcement on Changing Audit Institution for 2026
- Announcement on Expanding Business Scope and Amending "Articles of Association"
Follow Sunshine Guojian Pharmaceutical (Shanghai) into a list and get an email when it puts out news.
Follow Sunshine Guojian Pharmaceutical (Shanghai)